1
|
Broocks G, Meyer L, Bechstein M, Elsayed S, Schön G, Kniep H, Kemmling A, Hanning U, Fiehler J, McDonough RV. Penumbra salvage in extensive stroke: exploring limits for reperfusion therapy. J Neurointerv Surg 2023; 15:e419-e425. [PMID: 36878689 DOI: 10.1136/jnis-2022-020025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 02/17/2023] [Indexed: 03/08/2023]
Abstract
BACKGROUND The effect of thrombectomy in patients presenting with extensive ischemic stroke at baseline is currently being investigated; it remains uncertain to what extent brain tissue may be saved by reperfusion in such patients. Penumbra salvage volume (PSV) has been described as a tool to measure the volume of rescued penumbra. OBJECTIVE To assess whether the effect of recanalization on PSV is dependent on the extent of early ischemic changes. METHODS Observational study of patients with anterior circulation ischemic stroke triaged by multimodal-CT undergoing thrombectomy. PSV was defined as the difference between baseline penumbra volume and net infarct growth to follow-up. The effect of vessel recanalization on PSV depending on the extent of early ischemic changes (defined using Alberta Stroke Program Early CT Score (ASPECTS) and core volumes based on relative cerebral blood flow) was determined using multivariable linear regression analysis, and the association with functional outcome at day 90 was tested using multivariable logistic regression. RESULTS 384 patients were included, of whom 292 (76%) achieved successful recanalization (modified Thrombolysis in Cerebral Infarction ≥2b). Successful recanalization was independently associated with 59 mL PSV (95% CI 29.8 to 88.8 mL) and was linked to increased penumbra salvage up to an ASPECTS of 3 and core volume up to 110 mL. Recanalization was associated with a higher probability of a modified Rankin Scale score of ≤2 up to a core volume of 100 mL. CONCLUSIONS Recanalization was associated with significant penumbra salvage up to a lower ASPECTS margin of 3 and upper core volume margin of 110 mL. The clinical benefit of recanalization for patients with very large ischemic regions of >100 mL or ASPECTS <3 remains uncertain and requires prospective investigation.
Collapse
Affiliation(s)
- Gabriel Broocks
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Lukas Meyer
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Matthias Bechstein
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Sarah Elsayed
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Gerhard Schön
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Helge Kniep
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Uta Hanning
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jens Fiehler
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Rosalie V McDonough
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
2
|
Abdollahifard S, Taherifard E, Sadeghi A, Kiadeh PRH, Yousefi O, Mowla A. Endovascular therapy for acute stroke with a large infarct core: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2023; 32:107427. [PMID: 37925765 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 10/09/2023] [Accepted: 10/12/2023] [Indexed: 11/07/2023] Open
Abstract
OBJECTIVE In this meta-analysis, we aimed to investigate the efficacy and safety of endovascular treatment (EVT) for acute ischemic stroke (AIS) patients with large core infarct. METHODS Three online databases of Web of Science, PubMed and Scopus were systematically searched. Original studies which evaluated AIS participants with large core infarction who underwent EVT were included. R statistical software was used for statistical analyses. Effect sizes were presented with odds ratios (ORs) with their 95% confidence intervals (CIs). The effect sizes were pooled using random effects modeling. RESULTS Including 47 studies and 15,173 patients, this meta-analysis showed that compared with medical management (MM), EVT was significantly associated with decreased odds of mortality (0.67, 95% CI: 0.51-0.87) and increased odds of favorable outcomes, including a modified Rankin Scale of 0-3 (2.36, 95% CI: 1.69-3.291) and of 0-2 (3.54, 95% CI: 1.96-6.4) in 90 days and remarkable improvement in National Institutes of Health Stroke Scale within 48 h after the procedure (3.6, 95% CI:1.32-9.79). Besides, there was a higher chance of intracranial hemorrhage (ICH) development (1.88, 95% CI: 1.32-2.68) but not symptomatic ICH (1.34, 95% CI: 0.78-2.31) in those who underwent EVT. CONCLUSION Our study suggests that EVT might be an effective and relatively safe treatment option for the treatment of AIS patients with large vessel occlusion who have large core infarcts, although more large-scale trials are needed to consolidate the results and to make inclusion criteria and the patient selection process clearer.
Collapse
Affiliation(s)
| | - Erfan Taherifard
- School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; MPH Department, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Alireza Sadeghi
- School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | - Omid Yousefi
- Trauma Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ashkan Mowla
- Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California (USC), 1200 North State St., Suite 3300, Los Angeles, CA 90033, USA.
| |
Collapse
|
3
|
Wei W, Zhang J, Xie S, Fan D, Chen Y, Zhong C, Chen L, Zhang Y, Shi S. Endovascular therapy versus medical management for acute ischemic stroke with large infarct core: Systematic review and meta-analysis of randomized controlled trials. Clin Neurol Neurosurg 2023; 234:108007. [PMID: 37797364 DOI: 10.1016/j.clineuro.2023.108007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 09/29/2023] [Indexed: 10/07/2023]
Abstract
OBJECTIVE To compare the efficacy and safety of endovascular therapy (EVT) versus best medical management (BMM) in patients with acute ischemic stroke (AIS) with large infarct core. METHODS We searched Pubmed, Embase and Cochrane Central Register of Controlled Trials for published randomized clinical trials (RCTs) from inception to February 18, 2023. We defined patients with large core infarcts as having an Alberta Stroke Program early computed tomography score (ASPECTS) of 3-5. The primary outcome was functional independence, defined as a score of 0-2 on the modified Rankin scale (mRS) at 90 days. Secondary outcome was independent ambulation defined as mRS 0-3 at 90 days. Safety outcomes were mortality at 90 days, symptomatic intracranial hemorrhage (sICH) and any intracranial hemorrhage (ICH). RESULTS The overall treatment effect was more favourable to EVT group. EVT was significantly correlated with improvement of functional independence at 90 days (mRS 0-2) (RR = 2.40; 95 % CI, 1.82-3.16; P < 0.01; I2 = 0 %) and independent ambulation (mRS 0-3) (RR = 1,78; 95 % CI, 1.28-2.48; P < 0.01; I2 = 58 %) at 90 days. 90-day mortality was not significantly different between the two groups(RR = 0.95; 95 % CI, 0.78-1.16; P > 0.05; I2 = 0 %). The risk of sICH and any ICH was higher in EVT group than in BMM group. CONCLUSION Compared with BMM, EVT may improve functional outcomes in patients with ASPECTS 3-5, despite being associated with an increased risk of sICH and any ICH.
Collapse
Affiliation(s)
- Wenqian Wei
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Jian Zhang
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Shuyu Xie
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Dongmei Fan
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Yiyun Chen
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Chongxu Zhong
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Liufei Chen
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China
| | - Yueling Zhang
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China.
| | - Shengliang Shi
- Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, No. 166 Daxuedong Road, Nanning, Guangxi 530007, China.
| |
Collapse
|
4
|
Li Q, Abdalkader M, Siegler JE, Yaghi S, Sarraj A, Campbell BCV, Yoo AJ, Zaidat OO, Kaesmacher J, Pujara D, Nogueira RG, Saver JL, Li L, Han Q, Dai Y, Sang H, Yang Q, Nguyen TN, Qiu Z. Mechanical Thrombectomy for Large Ischemic Stroke: A Systematic Review and Meta-analysis. Neurology 2023; 101:e922-e932. [PMID: 37277200 PMCID: PMC10501098 DOI: 10.1212/wnl.0000000000207536] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 05/04/2023] [Indexed: 06/07/2023] Open
Abstract
BACKGROUND AND OBJECTIVES There is growing evidence for endovascular thrombectomy (EVT) in patients with large ischemic core infarct and large vessel occlusion (LVO). The objective of this study was to compare the efficacy and safety of EVT vs medical management (MM) using a systematic review and meta-analysis of observational studies and randomized controlled trials (RCTs). METHODS We searched the PubMed, Embase, Cochrane Library, and Web of Science databases to obtain articles related to mechanical thrombectomy for large ischemic core from inception until February 10, 2023. The primary outcome was independent ambulation (modified Rankin Scale [mRS] 0-3). Effect sizes were computed as risk ratio (RR) with random-effect or fixed-effect models. The quality of articles was evaluated through the Cochrane risk assessment tool and the Newcastle-Ottawa Scale. This study was registered in PROSPERO (CRD42023396232). RESULTS A total of 5,395 articles were obtained through the search and articles that did not meet the inclusion criteria were excluded by review of the title, abstract, and full text. Finally, 3 RCTs and 10 cohort studies met the inclusion criteria. The RCT analysis showed that EVT improved the 90-day functional outcomes of patients with large ischemic core with high-quality evidence, including independent ambulation (mRS 0-3: RR 1.78, 95% CI 1.28-2.48, p < 0.001) and functional independence (mRS 0-2: RR 2.59, 95% CI 1.89-3.57, p < 0.001), but without significantly increasing the risk of symptomatic intracranial hemorrhage (sICH: RR 1.83, 95% CI 0.95-3.55, p = 0.07) or early mortality (RR 0.95, 95% CI 0.78-1.16, p = 0.61). Analysis of the cohort studies showed that EVT improved functional outcomes of patients without an increase in the incidence in sICH. DISCUSSION This systematic review and meta-analysis indicates that in patients with LVO stroke with a large ischemic core, EVT was associated with improved functional outcomes over MM without increasing sICH risk. The results of ongoing RCTs may provide further insight in this patient population.
Collapse
Affiliation(s)
- Qi Li
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Mohamad Abdalkader
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - James E Siegler
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Shadi Yaghi
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Amrou Sarraj
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Bruce C V Campbell
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Albert J Yoo
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Osama O Zaidat
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Johannes Kaesmacher
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Deep Pujara
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Raul G Nogueira
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Jeffrey L Saver
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Lei Li
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Qin Han
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA.
| | - Yi Dai
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Hongfei Sang
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Qingwu Yang
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA
| | - Thanh N Nguyen
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA.
| | - Zhongming Qiu
- From the Department of Neurology (Q.L., Q.H., Y.D., Z.Q.), the 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA; Cooper Neurological Institute (J.E.S.), Cooper University Hospital, Camden, NJ; Rhode Island Hospital (S.Y.), Brown University, Providence; University Hospitals Cleveland Medical Center (A.S., D.P.), Case Western Reserve University, OH; Medicine and Neurology (B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Texas Stroke Institute (A.J.Y.), Dallas Fort Worth; Neuroscience and Stroke Program (O.O.Z.), Bon Secours Mercy Health St Vincent Hospital, Toledo, OH; University Institute of Diagnostic and Interventional Neuroradiology (J.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Neurology and Neurosurgery (R.G.N.), University of Pittsburgh Medical Center, PA; Neurology (J.L.S.), University of California in Los Angeles; Neurology (L.L.), The Second Affiliated Hospital of Harbin Medical University, China; Neurology (H.S.), Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou; Neurology (Q.Y.), Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqinq, China; and Department of Neurology (T.N.N.), Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA.
| |
Collapse
|
5
|
Neurological Functional Independence After Endovascular Thrombectomy and Different Imaging Modalities for Large Infarct Core Assessment : A Systematic Review and Meta-analysis. Clin Neuroradiol 2023; 33:21-29. [PMID: 35920865 DOI: 10.1007/s00062-022-01202-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Accepted: 07/10/2022] [Indexed: 11/03/2022]
Abstract
PURPOSE To investigate the rate of neurological functional independence (NFI) at 90 days in patients with large infarct core (LIC), which was evaluated by different imaging modalities before endovascular thrombectomy (EVT). METHODS PubMed and EMBASE were searched for original studies on clinical functional outcomes at 90 days in LIC patients who received EVT treatment from inception to 28 September 2021. The pooled NFI rates were calculated using random effects model according to different imaging modalities and criteria. RESULTS We included 34 studies enrolling 2997 LIC patients. The NFI rates were 23% (95% confidence interval, CI 15-32%) and 24% (95% CI 10-38%) when LIC was defined as core volume ≥50 ml and ≥ 70 ml separately on computed tomography perfusion, 36% (95% CI 23-48%) and 21% (95% CI 17-25%) when LIC was defined as core volume ≥ 50 ml and ≥ 70 ml separately on magnetic resonance diffusion-weighted imaging (DWI), 28% (95% CI 24-32%) and 37% (95% CI 21-53%) when LIC was defined as DWI-ASPECTS ≤ 5 and ≤ 6 separately, 23% (95% CI 19-27%) and 32% (95% CI 18-46%) when LIC was defined as NCCT-ASPECTS ≤ 5 and ≤ 6 separately. CONCLUSION Similar NFI rates could be obtained after EVT in LIC patients if proper LIC criteria were select according to the imaging modality.
Collapse
|
6
|
Garcia-Esperon C, Bivard A, Johns H, Chen C, Churilov L, Lin L, Butcher K, Kleinig TJ, Choi PMC, Cheng X, Dong Q, Aviv RI, Miteff F, Spratt NJ, Levi CR, Parsons MW. Association of Endovascular Thrombectomy With Functional Outcome in Patients With Acute Stroke With a Large Ischemic Core. Neurology 2022; 99:e1345-e1355. [PMID: 35803723 DOI: 10.1212/wnl.0000000000200908] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 05/16/2022] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Endovascular thrombectomy (EVT) is effective for patients with large vessel occlusion (LVO) stroke with smaller volumes of CT perfusion (CTP)-defined ischemic core. However, the benefit of EVT is unclear in those with a core volume >70 mL. We aimed to compare outcomes of EVT and non-EVT patients with an ischemic core volume ≥70 mL, hypothesizing that there would be a benefit from EVT for fair outcome (3-month modified Rankin scale [mRS] 0-3) after stroke. METHODS A retrospective analysis of patients enrolled into a multicenter (Australia, China, and Canada) registry (2012-2020) who underwent CTP within 24 hours of stroke onset and had a baseline ischemic core volume ≥70 mL was performed. The primary outcome was the estimation of the association of EVT in patients with core volume ≥70 mL and within 70-100 and ≥100 mL subgroups with fair outcome. RESULTS Of the 3,283 patients in the registry, 299 had CTP core volume ≥70 mL and 269 complete data (135 had core volume between 70 and 100 mL and 134 had core volume ≥100 mL). EVT was performed in 121 (45%) patients. EVT-treated patients were younger (median 69 vs 75 years; p = 0.011), had lower prestroke mRS, and smaller median core volumes (92 [79-116.5] mL vs 105.5 [85.75-138] mL, p = 0.004). EVT-treated patients had higher odds of achieving fair outcome in adjusted analysis (30% vs 13.9% in the non-EVT group; adjusted odds ratio [aOR] 2.1, 95% CI 1-4.2, p = 0.038). The benefit was seen predominantly in those with 70-100 mL core volume (71/135 [52.6%] EVT-treated), with 54.3% in the EVT-treated vs 21% in the non-EVT group achieving a fair outcome (aOR 2.5, 95% CI 1-6.2, p = 0.005). Of those with a core volume ≥100 mL, 50 of the 134 (37.3%) underwent EVT. Proportions of fair outcome were very low in both groups (8.1% vs 8.7%; p = 0.908). DISCUSSION We found a positive association of EVT with the 3-month outcome after stroke in patients with a baseline CTP ischemic core volume 70-100 mL but not in those with core volume ≥100 mL. Randomized data to confirm these findings are required. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that EVT is associated with better motor outcomes 3 months after CTP-defined ischemic stroke with a core volume of 70-100 mL.
Collapse
Affiliation(s)
- Carlos Garcia-Esperon
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia.
| | - Andrew Bivard
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Hannah Johns
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Chushuang Chen
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Leonid Churilov
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Longting Lin
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Kenneth Butcher
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Timothy J Kleinig
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Philip M C Choi
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Xin Cheng
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Qiang Dong
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Richard I Aviv
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Ferdinand Miteff
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Neil J Spratt
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Christopher R Levi
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | - Mark W Parsons
- From the Department of Neurology (C.G.-E., F.M., N.J.S., C.R.L.), John Hunter Hospital, New Lambton Heights; College of Health, Medicine, and Wellbeing (C.G.-E., F.M., N.J.S., C.R.L., M.W.P.), University of Newcastle; Hunter Medical Research Institute (C.G.-E., C.C., L.L., F.M., N.J.S., C.R.L., M.W.P.), Newcastle; Melbourne Brain Center at the Royal Melbourne Hospital (A.B., H.J., L.C., M.W.P.), University of Melbourne, Parkville; Melbourne Medical School (H.J., L.C.), University of Melbourne, Victoria; Prince of Wales Clinical School (K.B.), University of New South Wales, Sydney; Royal Adelaide Hospital (T.J.K.); Box Hill Hospital (P.M.C.C.), Melbourne; Eastern Health Clinical School (P.M.C.C.), Monash University, Melbourne, Australia; Huashan Hospital (X.C., Q.D.), Fudan University, Shanghai, China; Neuroradiology Section (R.I.A.), Department of Radiology, The Ottawa Hospital and University of Ottawa, Ontario, Canada; and Department of Neurology (L.L., M.W.P.), Liverpool Hospital, Ingham Institute for Applied Medical Research, University of New South Wales South Western Sydney Clinical School, Australia
| | | |
Collapse
|
7
|
Katyal A, Bhaskar SMM. Value of pre-intervention computed tomography perfusion imaging in the assessment of tissue outcome and long-term clinical prognosis in patients with anterior circulation acute ischemic stroke receiving reperfusion therapy: a systematic review. Acta Radiol 2022; 63:1243-1254. [PMID: 34342497 DOI: 10.1177/02841851211035892] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Computed tomography perfusion (CTP) imaging has emerged as an important adjunct to the current armamentarium of acute ischemic stroke (AIS) workflow. However, its adoption in routine clinical practice is far from optimal. PURPOSE To investigate the putative association of CTP imaging biomarkers in the assessment of prognosis in acute ischemic stroke. MATERIAL AND METHODS We performed a systematic review of the literature using MEDLINE, EMBASE, and Cochrane Central Register of Clinical Trials focusing on CTP biomarkers, tissue-based and clinical-based patient outcomes. We included randomized controlled trials, prospective cohort studies, and case-controlled studies published from January 2005 to 28 August 2020. Two independent reviewers conducted the study appraisal, data extraction, and quality assessment of the studies. RESULTS A total of 60 full-text studies were included in the final systematic review analysis. Increasing infarct core volume is associated with reduced odds of achieving functional independence (modified Rankin score 0-2) at 90 days and is correlated with the final infarct volume when reperfusion is achieved. CONCLUSION CTP has value in assessing tissue perfusion status in the hyperacute stroke setting and the long-term clinical prognosis of patients with AIS receiving reperfusion therapy. However, the prognostic use of CTP requires optimization and further validation.
Collapse
Affiliation(s)
- Anubhav Katyal
- Neurovascular Imaging Laboratory, Ingham Institute for Applied Medical Research, Clinical Sciences Stream, Sydney, NSW, Australia.,University of New South Wales (UNSW), South West Sydney Clinical School, Sydney, NSW, Australia
| | - Sonu Menachem Maimonides Bhaskar
- Neurovascular Imaging Laboratory, Ingham Institute for Applied Medical Research, Clinical Sciences Stream, Sydney, NSW, Australia.,Liverpool Hospital & South West Sydney Local Health District (SWSLHD), Department of Neurology & Neurophysiology, Sydney, NSW, Australia.,NSW Brain Clot Bank, NSW Health Pathology, Sydney, NSW, Australia.,Thrombolysis and Endovascular WorkFLOw Network (TEFLON), Sydney, NSW, Australia
| |
Collapse
|
8
|
Pillai Perianen P, Yan B. Are We Ready to Offer Endovascular Thrombectomy to All Patients With Large Ischemic Core? Front Neurol 2022; 13:893975. [PMID: 35493819 PMCID: PMC9043548 DOI: 10.3389/fneur.2022.893975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 03/18/2022] [Indexed: 11/13/2022] Open
|
9
|
Jiang Q, Wang H, Ge J, Hou J, Liu M, Huang Z, Guo Z, You S, Cao Y, Xiao G. Mechanical thrombectomy versus medical care alone in large ischemic core: An up-to-date meta-analysis. Interv Neuroradiol 2022; 28:104-114. [PMID: 33990150 PMCID: PMC8905077 DOI: 10.1177/15910199211016258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
OBJECTIVE We compared outcomes and adverse events of thrombectomy versus medical management in acute ischemic stroke (AIS) patients with baseline large infarct core. METHODS We searched Ovid MEDLINE(R) ALL, Cochrane Library Clinical Controlled Trials and EMBASE from inception to January 2021 for studies comparing thrombectomy and medical management alone in AIS patients who had ASPECTS <=7 or ischemic core volume >=50 ml. Imaging modalities to valuate ASPECTS and core volume were without restriction. The functional outcome was measured by mRS (modified Rankin Scale) score 0-2 at 90 days or discharge. The safety end point included the rates of mortality and sICH (symptomatic intracranial hemorrhage) or PH2 (parenchymal hematoma type 2). RESULTS Fourteen studies with a total of 2547 patients (thrombectomy n = [1197]; medical care alone [n = 1350]) fulfilled our criteria. As for patients with low ASPECTS, pooled results indicated a higher odds of good functional outcome (OR = 3.47; 95% CI 1.99 to 6.07; P < 0.0001, I2=66%) and a lower risk of mortality (OR = 0.62; 95% CI 0.46 to 0.83; P = 0.001, I2=32%) in thrombectomy group compared with no thrombectomy group, but the risk of sICH or PH2 did not differ between two groups. As for patients with large core volume, both functional outcome and safety end point between two groups showed no statistically significant difference. CONCLUSION Thrombectomy remained safe and effective by careful selection in patients with low ASPECTS. More studies were warranted to explore contraindications for mechanical thrombectomy in AIS patients, especially in patients with large core volume.
Collapse
Affiliation(s)
| | | | | | | | | | - Zhichao Huang
- Zhichao Huang, Department of Neurology, Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, 215004 Suzhou, Jiangsu, China.
| | | | | | | | - Guodong Xiao
- Guodong Xiao, Department of Neurology, Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, 215004 Suzhou, Jiangsu, China.
| |
Collapse
|
10
|
Katyal A, Bhaskar SMM. Value of pre-intervention CT perfusion imaging in acute ischemic stroke prognosis. DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (ANKARA, TURKEY) 2021; 27:774-785. [PMID: 34792033 DOI: 10.5152/dir.2021.20805] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Noninvasive imaging plays an important role in acute stroke towards diagnosis and ongoing management of patients. Systemic thrombolysis and endovascular thrombectomy (EVT) are proven treatments currently used in standards of care in acute stroke settings. The role of computed tomography angiography (CTA) in selecting patients with large vessel occlusion for EVT is well established. However, the value of CT perfusion (CTP) imaging in predicting outcomes after stroke remains ambiguous. This article critically evaluates the value of multimodal CT imaging in early diagnosis and prognosis of acute ischemic stroke with a focus on the role of CTP in delineating tissue characteristics, patient selection, and outcomes after reperfusion therapy. Insights on various technical and clinical considerations relevant to CTP applications in acute ischemic stroke, recommendations for existing workflow, and future areas of research are discussed.
Collapse
Affiliation(s)
- Anubhav Katyal
- Neurovascular Imaging Laboratory, Ingham Institute for Applied Medical Research, Clinical Sciences Stream, Sydney, Australia; University of New South Wales (UNSW), South Western Sydney Clinical School, NSW, Australia
| | - Sonu Menachem Maimonides Bhaskar
- Neurovascular Imaging Laboratory, Ingham Institute for Applied Medical Research, Clinical Sciences Stream, Sydney, Australia; Department of Neurology - Neurophysiology, Liverpool Hospital - South West Sydney Local Health District (SWSLHD), Sydney, Australia;University of New South Wales (UNSW), South Western Sydney Clinical School, NSW, Australia; Ingham Institute for Applied Medical Research, Stroke - Neurology Research Group, Sydney, Australia; NSW Brain Clot Bank, NSW Health Statewide Biobank and NSW Health Pathology, Sydney, NSW, Australia;Thrombolysis and Endovascular WorkFLOw Network (TEFLON), Sydney, Australia
| |
Collapse
|
11
|
Xie Y, Oster J, Micard E, Chen B, Douros IK, Liao L, Zhu F, Soudant M, Felblinger J, Guillemin F, Hossu G, Bracard S. Impact of Pretreatment Ischemic Location on Functional Outcome after Thrombectomy. Diagnostics (Basel) 2021; 11:diagnostics11112038. [PMID: 34829385 PMCID: PMC8625281 DOI: 10.3390/diagnostics11112038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 10/27/2021] [Accepted: 10/28/2021] [Indexed: 11/16/2022] Open
Abstract
Pretreatment ischemic location may be an important determinant for functional outcome prediction in acute ischemic stroke. In total, 143 anterior circulation ischemic stroke patients in the THRACE study were included. Ischemic lesions were semi-automatically segmented on pretreatment diffusion-weighted imaging and registered on brain atlases. The percentage of ischemic tissue in each atlas-segmented region was calculated. Statistical models with logistic regression and support vector machine were built to analyze the predictors of functional outcome. The investigated parameters included: age, baseline National Institutes of Health Stroke Scale score, and lesional volume (three-parameter model), together with the ischemic percentage in each atlas-segmented region (four-parameter model). The support vector machine with radial basis functions outperformed logistic regression in prediction accuracy. The support vector machine three-parameter model demonstrated an area under the curve of 0.77, while the four-parameter model achieved a higher area under the curve (0.82). Regions with marked impacts on outcome prediction were the uncinate fasciculus, postcentral gyrus, putamen, middle occipital gyrus, supramarginal gyrus, and posterior corona radiata in the left hemisphere; and the uncinate fasciculus, paracentral lobule, temporal pole, hippocampus, inferior occipital gyrus, middle temporal gyrus, pallidum, and anterior limb of the internal capsule in the right hemisphere. In conclusion, pretreatment ischemic location provided significant prognostic information for functional outcome in ischemic stroke.
Collapse
Affiliation(s)
- Yu Xie
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan 430000, China
| | - Julien Oster
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
| | - Emilien Micard
- CIC, Innovation Technologique, Université de Lorraine, Inserm, CHRU-Nancy, F-54000 Nancy, France;
| | - Bailiang Chen
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- CIC, Innovation Technologique, Université de Lorraine, Inserm, CHRU-Nancy, F-54000 Nancy, France;
| | - Ioannis K. Douros
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- Université de Lorraine, CNRS, Inria, LORIA, F-54000 Nancy, France
| | - Liang Liao
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- Department of Diagnostic and Interventional Neuroradiology, CHRU Nancy, F-54000 Nancy, France
| | - François Zhu
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- Department of Diagnostic and Interventional Neuroradiology, CHRU Nancy, F-54000 Nancy, France
| | - Marc Soudant
- CIC, Epidémiologie Clinique, Université de Lorraine, Inserm, CHRU-Nancy, F-54000 Nancy, France; (M.S.); (F.G.)
| | - Jacques Felblinger
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- CIC, Innovation Technologique, Université de Lorraine, Inserm, CHRU-Nancy, F-54000 Nancy, France;
| | - Francis Guillemin
- CIC, Epidémiologie Clinique, Université de Lorraine, Inserm, CHRU-Nancy, F-54000 Nancy, France; (M.S.); (F.G.)
| | - Gabriela Hossu
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- CIC, Innovation Technologique, Université de Lorraine, Inserm, CHRU-Nancy, F-54000 Nancy, France;
| | - Serge Bracard
- IADI, Université De Lorraine, INSERM, F-54000 Nancy, France; (Y.X.); (J.O.); (B.C.); (I.K.D.); (L.L.); (F.Z.); (J.F.); (G.H.)
- Department of Diagnostic and Interventional Neuroradiology, CHRU Nancy, F-54000 Nancy, France
- Correspondence: ; Tel.: +33-383851773
| | | |
Collapse
|
12
|
Novel Imaging Biomarker Prediction of Parenchymal Hemorrhage after Mechanical Thrombectomy in Patients with Large Ischemic Core. J Stroke Cerebrovasc Dis 2021; 31:106125. [PMID: 34706293 DOI: 10.1016/j.jstrokecerebrovasdis.2021.106125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 09/03/2021] [Accepted: 09/14/2021] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Recently studies have shown that select acute ischemic stroke (AIS) patients with large ischemic core could be deemed as reasonable candidates to receive mechanical thrombectomy (MT) with low risk of developing parenchymal hemorrhage (PH) or symptomatic intracerebral hemorrhage (sICH); however, the selection criterion remains lacking. Our study aims to investigate the relationship between a novel imaging biomarker of largest core mass volume (LCMV) and development of PH in stroke patients with large ischemic core who have undergone MT. METHODS A total of 26 AIS patients with large ischemic core (defined as ischemic core volume ≧ 50 ml) were enrolled in the study. Volume of ischemic core and the LCMV measured with Mistar software were measured in all patients. Fourteen patients with AIS developed PH while 12 patients showed no signs of PH based on CT imaging obtained between 24 h and 3 day after MT. We compared the volume of ischemic core and LCMV between two groups. RESULTS Volume of ischemic core showed no significant difference between the PH and no PH group [105.5 (62.4-131.5) vs 75.0 (56.3-102.2), p = 0.105], whereas LCMV was significantly higher in the PH (14.80 ± 5.23) vs. no PH group (8.40 ± 2.61, p = 0.001). ROC analysis revealed that LCMV was positively correlated with PH (area under the curve = 0.905). The optimal LCMV associated with PH was ≧ 9.67 ml. CONCLUSION LCMV is an effective and easy-to-use imaging biomarker to predict PH after MT in AIS patients with large ischemic core.
Collapse
|
13
|
Kerleroux B, Janot K, Hak JF, Kaesmacher J, Hassen WB, Benzakoun J, Oppenheim C, Herbreteau D, Ifergan H, Bricout N, Henon H, Yoshimoto T, Inoue M, Consoli A, Costalat V, Naggara O, Lapergue B, Cagnazzo F, Boulouis G. Mechanical Thrombectomy in Patients with a Large Ischemic Volume at Presentation: Systematic Review and Meta-Analysis. J Stroke 2021; 23:358-366. [PMID: 34649380 PMCID: PMC8521249 DOI: 10.5853/jos.2021.00724] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 07/12/2021] [Indexed: 12/25/2022] Open
Abstract
The benefits of mechanical thrombectomy (MT) for patients with acute ischemic stroke (AIS) and a large ischemic core (LIC) at presentation are uncertain. We aimed to obtain up-to-date aggregate estimates of the outcomes following MT in patients with volumetrically assessed LIC. We conducted a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-conformed, PROSPERO-registered, systematic review and meta-analysis of studies that included patients with AIS and a baseline LIC treated with MT, reported ischemic core volume quantitatively, and included patients with a LIC defined as a core volume ≥50 mL. The search was restricted to studies published between January 2015 and June 2020. Random-effects-meta-analysis was used to assess the effect of MT on 90-day unfavorable outcome (i.e., modified Rankin Scale [mRS] 3–6), mortality, and symptomatic intracranial hemorrhage (sICH) occurrence. Sensitivity analyses were performed for imaging-modality (computed tomography-perfusion or magnetic resonance-diffusion weighted imaging) and LIC-definition (≥50 or ≥70 mL). We analyzed 10 studies (954 patients), including six (682 patients) with a control group, allowing to compare 332 patients with MT to 350 who received best-medical-management alone. Overall, after MT the rate of patients with mRS 3–6 at 90 days was 74% (99% confidence interval [CI], 67 to 84; Z-value=7.04; I2=92.3%) and the rate of 90-day mortality was 36% (99% CI, 33 to 40; Z-value=–7.07; I2=74.5). Receiving MT was associated with a significant decrease in mRS 3–6 odds ratio (OR) 0.19 (99% CI, 0.11 to 0.33; P<0.01; Z-value=–5.92; I2=62.56) and in mortality OR 0.60 (99% CI, 0.34 to 1.06; P=0.02; Z-value=–2.30; I2=58.72). Treatment group did not influence the proportion of patients experiencing sICH, OR 0.96 (99% CI, 0.2 to 1.49; P=0.54; Z-value=–0.63; I2=64.74). Neither imaging modality for core assessment, nor LIC definition influenced the aggregated outcomes. Using aggregate estimates, MT appeared to decrease the risk of unfavorable functional outcome in patients with a LIC assessed volumetrically at baseline.
Collapse
Affiliation(s)
- Basile Kerleroux
- Department of Neuroradiology, GHU Paris, Sainte Anne Hospital Pscyhiatry and Neurosciences Institute (IPNP), UMR_S1266, INSERM, University of Paris, Tours, France
| | - Kevin Janot
- Department of Neuroradiology, University Hospital of Tours, Tours, France
| | - Jean François Hak
- Department of Neuroradiology, University Hospital of Marseille La Timone, Marseille, France
| | - Johannes Kaesmacher
- Institute of Diagnostic, Interventional and Pediatric Radiology and Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland
| | - Wagih Ben Hassen
- Department of Neuroradiology, GHU Paris, Sainte Anne Hospital Pscyhiatry and Neurosciences Institute (IPNP), UMR_S1266, INSERM, University of Paris, Tours, France
| | - Joseph Benzakoun
- Department of Neuroradiology, GHU Paris, Sainte Anne Hospital Pscyhiatry and Neurosciences Institute (IPNP), UMR_S1266, INSERM, University of Paris, Tours, France
| | - Catherine Oppenheim
- Department of Neuroradiology, GHU Paris, Sainte Anne Hospital Pscyhiatry and Neurosciences Institute (IPNP), UMR_S1266, INSERM, University of Paris, Tours, France
| | - Denis Herbreteau
- Department of Neuroradiology, University Hospital of Tours, Tours, France
| | - Heloise Ifergan
- Department of Neuroradiology, University Hospital of Tours, Tours, France
| | - Nicolas Bricout
- Diagnostic and Interventional Neuroradiology, University Hospital of Lille, Lille, France
| | - Hilde Henon
- Neuroradiology Department and Stroke Unit, University Hospital of Lille, Lille, France
| | - Takeshi Yoshimoto
- Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center, Suita, Japan
| | - Manabu Inoue
- Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center, Suita, Japan
| | - Arturo Consoli
- Department of Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - Vincent Costalat
- Neuroradiology Department, University Hospital of Gui de Chauliac, Montpellier, France
| | - Olivier Naggara
- Department of Neuroradiology, GHU Paris, Sainte Anne Hospital Pscyhiatry and Neurosciences Institute (IPNP), UMR_S1266, INSERM, University of Paris, Tours, France
| | - Bertrand Lapergue
- Department of Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - Federico Cagnazzo
- Neuroradiology Department, University Hospital of Gui de Chauliac, Montpellier, France
| | - Grégoire Boulouis
- Department of Neuroradiology, GHU Paris, Sainte Anne Hospital Pscyhiatry and Neurosciences Institute (IPNP), UMR_S1266, INSERM, University of Paris, Tours, France.,Department of Neuroradiology, University Hospital of Tours, Tours, France
| |
Collapse
|
14
|
Campbell BCV, Lansberg MG, Broderick JP, Derdeyn CP, Khatri P, Sarraj A, Saver JL, Vagal A, Albers GW. Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice. Stroke 2021; 52:2723-2733. [PMID: 34233464 DOI: 10.1161/strokeaha.121.035132] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND AND PURPOSE The Stroke Treatment Academic Industry Roundtable (STAIR) sponsored an imaging session and workshop during the Stroke Treatment Academic Industry Roundtable XI via webinar on October 1 to 2, 2020, to develop consensus recommendations, particularly regarding optimal imaging at primary stroke centers. METHODS This forum brought together stroke neurologists, neuroradiologists, neuroimaging research scientists, members of the National Institute of Neurological Disorders and Stroke, industry representatives, and members of the US Food and Drug Administration to discuss imaging priorities in the light of developments in reperfusion therapies, particularly in an extended time window, and reinvigorated interest in brain cytoprotection trials. RESULTS The imaging session summarized and compared the imaging components of recent acute stroke trials and debated the optimal imaging strategy at primary stroke centers. The imaging workshop developed consensus recommendations for optimizing the acquisition, analysis, and interpretation of computed tomography and magnetic resonance acute stroke imaging, and also recommendations on imaging strategies for primary stroke centers. CONCLUSIONS Recent positive acute stroke clinical trials have extended the treatment window for reperfusion therapies using imaging selection. Achieving rapid and high-quality stroke imaging is therefore critical at both primary and comprehensive stroke centers. Recommendations for enhancing stroke imaging research are provided.
Collapse
Affiliation(s)
- Bruce C V Campbell
- Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C.), University of Melbourne, Parkville, Victoria, Australia.,Florey Institute of Neuroscience and Mental Health (B.C.V.C.), University of Melbourne, Parkville, Victoria, Australia
| | - Maarten G Lansberg
- Department of Neurology & Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., G.W.A.)
| | | | - Colin P Derdeyn
- Department of Radiology, Iowa Institute of Biomedical Imaging, University of Iowa Hospitals and Clinics (C.P.D.)
| | - Pooja Khatri
- Department of Neurology (J.P.B., P.K.), University of Cincinnati, OH
| | - Amrou Sarraj
- UT McGovern Medical School, Department of Neurology, Houston (A.S.)
| | - Jeffrey L Saver
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California Los Angeles (J.L.S.)
| | - Achala Vagal
- Department of Radiology (A.V.), University of Cincinnati, OH
| | - Gregory W Albers
- Department of Neurology & Stanford Stroke Center, Stanford University School of Medicine, CA (M.G.L., G.W.A.)
| | | |
Collapse
|
15
|
Nguyen TQ, Dang TQ, Phan HT, Nguyen TH. A Challenging Case: Endovascular Treatment in a Patient with Large Ischemic Core and Dramatic Recovery. Case Rep Neurol 2021; 12:56-62. [PMID: 33505273 DOI: 10.1159/000506974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 02/29/2020] [Indexed: 11/19/2022] Open
Abstract
Uncertainty exists over the efficacy and safety of endovascular treatment in patients with large ischemic cores in anterior circulation. Several trials have shown some potential benefits in selected patients despite their late presentation. In particular, perfusion imaging modalities equipped with automatic software has been proven useful in identifying patients with large ischemic cores that are at risk of infarct core expansion, meaning that this specific patient group could still benefit from reperfusion treatment. We reported a case of late-presenting and progressing acute ischemic stroke who was selected by perfusion imaging with RAPID software and successfully underwent endovascular thrombectomy. On admission, her National Institutes of Health Stroke Scale (NIHSS) score was 7. Computed tomography angiography showed complete occlusion of the proximal right middle cerebral artery. Subsequent advanced perfusion imaging with automatic software showed that the ischemic core was 88 mL, Tmax >6 s volume was 131 mL, and mismatch volume was 43 mL. She was rapidly transferred to the Cath lab for thrombectomy with a stent retriever. Her NIHSS score was 15 before the endovascular procedure. She had a dramatic recovery with an NIHSS score of 4 at 24-h after the procedure. She was discharged on day 9 with a modified Rankin Score of 1. Our findings suggest that endovascular treatment can be beneficial to the patients, particularly younger ones, with large ischemic cores with the aid of perfusion imaging.
Collapse
Affiliation(s)
| | - Tinh Quang Dang
- Ho Chi Minh City Medicine and Pharmacy University, Ho Chi Minh City, Vietnam
| | - Hoang Thi Phan
- 115 People's Hospital, Ho Chi Minh City, Vietnam.,Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.,Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
| | - Thang Huy Nguyen
- 115 People's Hospital, Ho Chi Minh City, Vietnam.,Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
| |
Collapse
|
16
|
Zhao Z, Zhang J, Jiang X, Wang L, Yin Z, Hall M, Wang Y, Lai L. Is Endovascular Treatment Still Good for Ischemic Stroke in Real World?: A Meta-Analysis of Randomized Control Trial and Observational Study in the Last Decade. Stroke 2020; 51:3250-3263. [PMID: 32921259 DOI: 10.1161/strokeaha.120.029742] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND PURPOSE Although endovascular treatment (EVT) for acute ischemic stroke is classified as I evidence, outcomes after EVT in real-world practice appear to be less superior than those in randomized clinical trials (RCTs). Additionally, the effect of EVT is unclear compared with medical treatment (MT) for patients with mild symptoms defined by National Institutes of Health Stroke Scale score <6 or with severe symptoms defined by Alberta Stroke Program Early CT Score <6. METHODS Literatures were searched in big databases and major meetings from December 6, 2009, to December 6, 2019, including RCTs and observational studies comparing EVT against MT for patients with acute ischemic stroke. Observational studies were precategorized into 3 groups based on imaging data on admission: mild stroke group with National Institutes of Health Stroke Scale score <6, severe stroke group with Alberta Stroke Program Early CT Score <6 or ischemic core ≥50 mL, and normal stroke group for all others. Outcome was measured as modified Rankin Scale score of 0 to 2, mortality at 90 days, and symptomatic intracranial hemorrhage (sICH) at 24 hours. RESULTS Fifteen RCTs (n=3694) and 37 observational studies (n=9090) were included. EVT was associated with higher modified Rankin Scale 0 to 2 rate and lower mortality in RCTs and normal stroke group, whereas EVT was associated with higher sICH rate in normal stroke group, and no difference of sICH rate appeared between EVT and MT in RCTs. In severe stroke group, EVT was associated with higher modified Rankin Scale 0 to 2 rate and lower mortality, whereas no difference of sICH rate was found. In mild stroke group, there was no difference in modified Rankin Scale 0 to 2 rate between EVT and MT, whereas EVT was associated with higher mortality and sICH rate. CONCLUSIONS Evidence from RCTs and observational studies supports the use of EVT as the first-line choice for eligible patients corresponding to the latest guideline. For patients with Alberta Stroke Program Early CT Score <6, EVT showed superiority over MT, also in line with the guidelines. On the contrary to the guideline, our data do not support EVT for patients with National Institutes of Health Stroke Scale score <6.
Collapse
Affiliation(s)
- Zixu Zhao
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China (Z.Z., J.Z., X.J., Y.W., L.L.).,Queen Mary School, Jiangxi Medical College (Z.Z., J.Z.), Nanchang University, Jiangxi, PR China
| | - Jiarui Zhang
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China (Z.Z., J.Z., X.J., Y.W., L.L.).,Queen Mary School, Jiangxi Medical College (Z.Z., J.Z.), Nanchang University, Jiangxi, PR China
| | - Xin Jiang
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China (Z.Z., J.Z., X.J., Y.W., L.L.).,The First Clinical Medical School, Jiangxi Medical College (X.J.), Nanchang University, Jiangxi, PR China
| | - Li Wang
- Centre for Evidence-Based Medicine, School of Public Health (L.W.), Nanchang University, Jiangxi, PR China
| | - Zixiao Yin
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, PR China (Z.Y.)
| | - Michael Hall
- Institute of Ophthalmology, University College London, United Kingdom (M.H.)
| | - Yang Wang
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China (Z.Z., J.Z., X.J., Y.W., L.L.)
| | - Lingfeng Lai
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Jiangxi, PR China (Z.Z., J.Z., X.J., Y.W., L.L.)
| |
Collapse
|
17
|
Jiang X, Zhao Z, Zhang Y, Lai L. The Safety and Efficacy of Endovascular Treatment for Patients With ASPECTS<6 in Anterior Circulation Stroke: A Meta-Analysis and Subgroup Analysis by Imaging Techniques. J Stroke Cerebrovasc Dis 2020; 29:105122. [PMID: 32912548 DOI: 10.1016/j.jstrokecerebrovasdis.2020.105122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 06/07/2020] [Accepted: 06/29/2020] [Indexed: 10/23/2022] Open
Abstract
BACKGROUND Endovascular treatment (EVT) is merely recommended as class of recommendation IIb for patients with ASPECTS <6 according to the American Heart Association guideline 2019. In addition, the best determined imaging technique for EVT in patient with ASPECTS<6 remains unknown. The objective of this study was to define the safety and efficacy of EVT for patients with ASPECTS<6 and investigate the superiority between MRI and CT for patient selection. METHODS A systematic search of PubMed, EMBASE, The Cochrane Library and other additional sources was performed for studies published with no publication period. Our study was conducted corresponding to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRIMA) guidelines. The analysis was performed using the Comprehensive Meta-Analysis (CMA) 2.0. RESULTS Five studies reporting data from 844 participants were included in our analysis according to the inclusion criteria. Consequently, EVT was associated with statistically significant higher functional independence compared with MT (OR 5.401, 95% CI 3.227-9.041). Whereas EVT was found to be related to lower mortality compared with MT based on eligible data (OR 0.461, 95% CI 0.329-0.647). No significant difference was identified in sICH between EVT and MT (OR 1.075, 95% CI 0.452-2.558). CONCLUSION According to the results of our study, we suggested that EVT is a preferred therapy in ACS patients with ASPECTS<6 in consideration of efficacy and safety. Furthermore, MRI did not show superiority over CT as no statistical difference was detected in all subgroups.
Collapse
Affiliation(s)
- Xin Jiang
- Department of Neurosurgery, the First Affiliated Hospital of Nanchang University, 17 Yong Wai Zheng Street, East Lake District, 330006 Nanchang, Jiangxi, PR China; The First Clinical Medical School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, PR China
| | - Zixu Zhao
- Department of Neurosurgery, the First Affiliated Hospital of Nanchang University, 17 Yong Wai Zheng Street, East Lake District, 330006 Nanchang, Jiangxi, PR China; Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, PR China
| | - Ying Zhang
- The First Clinical Medical School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, PR China
| | - Lingfeng Lai
- Department of Neurosurgery, the First Affiliated Hospital of Nanchang University, 17 Yong Wai Zheng Street, East Lake District, 330006 Nanchang, Jiangxi, PR China.
| |
Collapse
|
18
|
The Clinical Usefulness of Targeted Temperature Management in Acute Ischemic Stroke with Malignant Trait After Endovascular Thrombectomy. Neurocrit Care 2020; 34:990-999. [PMID: 32812197 DOI: 10.1007/s12028-020-01069-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 07/27/2020] [Indexed: 01/19/2023]
Abstract
BACKGROUND/OBJECTIVE Targeted temperature management (TTM) may be more beneficial after endovascular treatment (EVT) in patients with a large ischemic core. Therefore, we assessed the usefulness of TTM for such patients from a multicenter endovascular registry. METHODS Anterior circulation stroke patients who underwent endovascular recanalization were included; acute ischemic stroke with malignant traits was designated as (1) baseline Alberta Stroke Program Early CT Score (ASPECTS) below 6 and (2) diffusion-weighted imaging (DWI) lesion volume measurement (> 82 ml) or National Institutes of Health Stroke Scale score > 20 and item Ia > 0. TTM (34.5 °C) was maintained for at least 48 h. RESULTS We evaluated baseline demographics, risk factors, EVT parameters, and clinical outcomes between the TTM and non-TTM groups. Among the 548 patients, the TTM group (n = 91) significantly had a lower baseline ASPECTS (p < 0.001) and a higher DWI volume (p < 0.001) than the non-TTM group (n = 457). TTM group had a lower prevalence of favorable outcome (0-2 of modified Rankin Scale at 3 months; p = 0.008) than the non-TTM group. In a subgroup analysis of malignant trait patients (n = 80), TTM patients (n = 28) had more favorable outcome (32.1% vs. 7.7% p = 0.009) and less hemorrhagic transformation (none vs. any hemorrhage, p = 0.007) than non-TTM patients (n = 52). After adjusting for potential outcome predictors, TTM (odds ratio [OR] 4.63; confidence interval [CI] 1.20-17.89; p = 0.026) and hypertension (OR 0.18; CI 0.04-0.74; p = 0.018) were found to be independent determinants. CONCLUSIONS Our data suggest that TTM attenuates impending hemorrhagic transformation and leads to favorable clinical outcomes in EVT patients with malignant trait.
Collapse
|
19
|
Sarraj A, Grotta JC, Pujara DK, Shaker F, Tsivgoulis G. Triage imaging and outcome measures for large core stroke thrombectomy – a systematic review and meta-analysis. J Neurointerv Surg 2020; 12:1172-1179. [DOI: 10.1136/neurintsurg-2019-015509] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 04/20/2020] [Accepted: 04/25/2020] [Indexed: 11/04/2022]
Abstract
BackgroundTrials of endovascular thrombectomy (EVT) mostly excluded patients with large core strokes so the safety and efficacy of EVT is not well established in such patients. Moreover, the definition of large core and its measurement differ between semi-quantitative (ASPECTS) and quantitative (core volume) imaging modalities. We evaluated functional and safety outcomes in studies reporting large core stroke patients treated with EVT and compared them with patients treated with medical management (MM) only.MethodsA systemic search using three large databases was performed to identify studies evaluating functional and safety outcomes in patients with large core strokes (ASPECTS<6 or core volume ≥50 cc) on CT, MRI, and Perfusion imaging according to PRISMA guidelines. A random-effect meta-analysis model was used to pool reported outcomes.ResultsTwelve studies reporting outcomes for patients treated with EVT compared with MM in large core strokes were included. A pooled random-effect meta-analysis of large core patients by either definition (ASPECTS <6 or ischemic core volume ≥50 cc or both) demonstrated increased functional independence (mRS-scores 0–2) rates with EVT (EVT: 122/491 (25%), MM: 45/691 (7%), pooled OR: 4.39 [95% CI: 2.53 to 7.64], overall effect Z-score: 5.25, P<0.00001, I2=37%, P for Cochran Q:0.15) and decreased mortality (EVT: 101/439 (23%), MM: 215/645 (33%), pooled OR:0.53 [95% CI: 0.40 to 0.71], overall effect Z-score:4.32, P<0.0001, I2=0%, P for Cochran Q:0.78) at 90 days, without significant increase in symptomatic intracranial hemorrhage (ICH) (EVT: 42/462 (9%), MM: 35/663 (5%), pooled OR: 1.68 [95% CI: 0.92 to 3.09], overall effect Z-score:1.68, P=0.09, I2=26%, P for Cochran Q:0.24). Similar effects were observed in studies reporting large core outcomes based on ASPECTS <6 and ischemic core volume ≥50 cc. We observed no heterogeneity between quantitative vs semi-quantitative large core definitions, different ischemic core thresholds, and studies reporting outcomes over different time windows in subgroup analyses.ConclusionIn large core stroke patients, EVT is associated with improved functional independence and lower mortality at 90 days without significant increase in symptomatic ICH across various definitions, thresholds of large core size, and time windows. Further randomized evidence is warranted to establish EVT efficacy and safety in this population.
Collapse
|
20
|
Demeestere J, Wouters A, Christensen S, Lemmens R, Lansberg MG. Review of Perfusion Imaging in Acute Ischemic Stroke: From Time to Tissue. Stroke 2020; 51:1017-1024. [PMID: 32008460 DOI: 10.1161/strokeaha.119.028337] [Citation(s) in RCA: 116] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jelle Demeestere
- From the Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Belgium (J.D., A.W., R.L.).,VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium (J.D., A.W., R.L.).,Department of Neurology, University Hospitals Leuven, Belgium (J.D., A.W., R.L.)
| | - Anke Wouters
- From the Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Belgium (J.D., A.W., R.L.).,VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium (J.D., A.W., R.L.).,Department of Neurology, University Hospitals Leuven, Belgium (J.D., A.W., R.L.)
| | - Soren Christensen
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA (S.C., M.G.L.)
| | - Robin Lemmens
- From the Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Belgium (J.D., A.W., R.L.).,VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium (J.D., A.W., R.L.).,Department of Neurology, University Hospitals Leuven, Belgium (J.D., A.W., R.L.)
| | - Maarten G Lansberg
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA (S.C., M.G.L.)
| |
Collapse
|
21
|
Rehani B, Ammanuel SG, Zhang Y, Smith W, Cooke DL, Hetts SW, Josephson SA, Kim A, Hemphill JC, Dillon W. A New Era of Extended Time Window Acute Stroke Interventions Guided by Imaging. Neurohospitalist 2019; 10:29-37. [PMID: 31839862 DOI: 10.1177/1941874419870701] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Ischemic stroke is one of the most debilitating and deadliest conditions worldwide. Intravenous t-PA is the current standard treatment within 4 hours after onset of symptoms. Recent randomized controlled trials have demonstrated the efficacy of neurointerventional intra-arterial treatment in acute ischemic stroke. About 20% of acute ischemic stroke are classified as wake-up strokes, which falls out of the conventional treatment time window. New evidence suggests that some patients with longer time from symptom onset (up to 24 hours) may benefit from thrombectomy, probably in part due to variations in collateral circulation among individual patients. Advanced imaging can play a crucial role in identifying patients who could benefit from endovascular intervention presenting within extended treatment time windows. In this article, we review the advanced imaging algorithm for ischemic stroke workup in the multiple studies published to date and summarize the results of the clinical trials for late ischemic stroke that can be clinically useful.
Collapse
Affiliation(s)
- Bhavya Rehani
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA
| | - Simon G Ammanuel
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA
| | - Yi Zhang
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA
| | - Wade Smith
- Department of Neurology, University of California San Francisco, CA, USA
| | - Daniel L Cooke
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA
| | - Steven W Hetts
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA
| | - S Andrew Josephson
- Department of Neurology, University of California San Francisco, CA, USA
| | - Anthony Kim
- Department of Neurology, University of California San Francisco, CA, USA
| | - J Claude Hemphill
- Department of Neurology, University of California San Francisco, CA, USA
| | - William Dillon
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA, USA
| |
Collapse
|